MktsMarkets

Alnylam Pharmaceuticals, Inc.
NASDAQ: ALNYKey statistics
ALNY News
Stories mentioning ALNY from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 | Q1 '24Mar 31 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1,097,033 | 1,249,026 | 773,689 | 594,189 | 593,166 | 500,919 | 659,825 | 494,333 |
| Cost of Goods Sold | 267,723 | 197,231 | 142,029 | 70,183 | 102,649 | 81,980 | 67,271 | 54,613 |
| Gross Profit | 829,310 | 1,051,795 | 631,660 | 524,006 | 490,517 | 418,939 | 592,554 | 439,720 |
| Operating Expenses | ||||||||
| Research & Development | 372,218 | 358,814 | 323,621 | 265,122 | 300,169 | 270,926 | 294,142 | 260,995 |
| Sales General & Admin | 325,374 | 322,076 | 323,314 | 239,949 | 295,339 | 220,993 | 248,397 | 210,797 |
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | 131,718 | 367,982 | (16,199) | 18,077 | (105,159) | (76,905) | 48,614 | (43,435) |
| Interest Income | 26,630 | 28,681 | 27,486 | 28,673 | 31,019 | 32,146 | 29,182 | 29,645 |
| Interest Expense | 35,253 | |||||||
| Other Expense | 76,562 | (74,150) | (6,399) | 9,191 | (80,847) | (29,528) | (55,705) | (14,544) |
| Pretax Income | 121,909 | 238,969 | (35,358) | (2,368) | (193,958) | (108,663) | (11,167) | (63,587) |
| Tax Provision | (25,282) | (12,115) | 30,919 | 15,883 | (110,195) | 2,907 | 5,722 | 2,348 |
| Net Income (Loss) | 147,191 | 251,084 | (66,277) | (18,251) | (83,763) | (111,570) | (16,889) | (65,935) |
| Earnings Per Share (Basic) | 1.12 | 1.91 | (0.51) | (0.14) | (0.66) | (0.87) | (0.13) | (0.52) |
| Earnings Per Share (Diluted) | 1.09 | 1.84 | (0.51) | (0.14) | (0.66) | (0.87) | (0.13) | (0.52) |
| Weighted Average Shares Outstanding (Basic) | 131,004 | 131,447 | 130,628 | 129,676 | 127,651 | 128,590 | 126,733 | 126,138 |
| Weighted Average Shares Outstanding (Diluted) | 134,684 | 137,348 | 130,628 | 129,676 | 127,651 | 128,590 | 126,733 | 126,138 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ALNY
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is a stock listed on the Nasdaq Stock Market under the ticker symbol ALNY. It last traded at $159.85 (Nov 11, 2026, 4:00 PM ET), up 5.4% on the day. That gives Alnylam Pharmaceuticals a market capitalisation of $20.3B and a price-to-earnings ratio of 7.5.
Over the past 52 weeks ALNY has traded between $149.18 and $479.79.
Revenue for the quarter ended Dec 31, 2025 was $1.1B; net income $147.2M. Revenue was up 84.9% from $593.2M in the quarter ended Dec 31, 2024.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Dec 31, 2025 | $1.1B | $147.2M | 13.4% |
| Sep 30, 2025 | $1.2B | $251.1M | 20.1% |
| Jun 30, 2025 | $773.7M | -$66.3M | -8.6% |
| Mar 31, 2025 | $594.2M | -$18.3M | -3.1% |
From Alnylam Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…